Bridget Burgess, MD
Otolaryngology · Weymouth, MANPI 1861734949
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 40 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 14 manufacturers reported payments, led by Sanofi at 27.3% of the total. Reporting peaked in 2024 at $281 and has fallen 84.5% since, to $44 in 2025.
Across 40 payments — averaging $22.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$250
- Regeneron Healthcare Solutions, Inc.$208
- GSK$154
- Intersect ENT, Inc.$74
- Mylan Pharmaceuticals Inc.$41
- Hikma Pharmaceuticals USA$28
- plus $160 from 8 others
What the payments were for
- Food & beverage$914100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 10 | $250 |
| Regeneron Healthcare Solutions, Inc. | 9 | $208 |
| GSK | 7 | $154 |
| Intersect ENT, Inc. | 2 | $74 |
| Mylan Pharmaceuticals Inc. | 2 | $41 |
| Hikma Pharmaceuticals USA | 2 | $28 |
| Inspire Medical Systems, Inc. | 1 | $26 |
| Optinose US, Inc. | 1 | $23 |
| Johnson & Johnson | 1 | $22 |
| Aerin Medical Inc. | 1 | $20 |
| Acera Surgical, Inc. | 1 | $19 |
| Davol Inc. | 1 | $18 |
| Merck | 1 | $16 |
| Acclarent, Inc | 1 | $15 |
How this compares
$914 in reported general payments places this provider in the 55th percentile of 298 otolaryngology providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Ipratropium Bromide | 76 | $2,600 |
| Ciprofloxacin-DexamethasoneCiprofloxacin Hcl/Dexameth | 21 | $2,191 |
| Azelastine Hcl | 42 | $1,077 |
| Fluocinolone Acetonide Oil | 12 | $602 |
| Fluticasone Propionate | 42 | $577 |
| Omeprazole | 27 | $521 |
| Clotrimazole | 11 | $474 |
| Fluconazole | 20 | $294 |
| Famotidine | 23 | $273 |
| Nortriptyline Hcl | 17 | $200 |
| Montelukast Sodium | 11 | $181 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 12 | $129 |
| Prednisone | 24 | $73 |
Paid to pharmacies, not to this prescriber.
Other otolaryngology in Weymouth
- Robin PappalWeymouth$4K
- Ayesha KhalidConcord$511K
- Dennis PoeBoston$264K
- Peter WeberBoston$157K
- Kevin EmerickBoston$89K
- Benjamin BleierBoston$77K
- Gregory RandolphBoston$56K
- Daniel LeeBoston$52K
- Pratik PradhanBrockton$51K
- Marika RussellBoston$50K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.